Next Article in Journal
Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy
Previous Article in Journal
An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
 
 
Review

Article Versions Notes

Cancers 2021, 13(4), 804; https://doi.org/10.3390/cancers13040804
Action Date Notes Link
article pdf uploaded. 15 February 2021 07:45 CET Version of Record https://www.mdpi.com/2072-6694/13/4/804/pdf-vor
article xml file uploaded 18 February 2021 03:02 CET Original file -
article xml uploaded. 18 February 2021 03:02 CET Update https://www.mdpi.com/2072-6694/13/4/804/xml
article pdf uploaded. 18 February 2021 03:02 CET Updated version of record https://www.mdpi.com/2072-6694/13/4/804/pdf
article html file updated 18 February 2021 06:03 CET Original file -
article html file updated 25 July 2022 03:33 CEST Update https://www.mdpi.com/2072-6694/13/4/804/html
Back to TopTop